[go: up one dir, main page]

AR037930A1 - Formulaciones de acitromicina directamente compresibles - Google Patents

Formulaciones de acitromicina directamente compresibles

Info

Publication number
AR037930A1
AR037930A1 ARP020105016A ARP020105016A AR037930A1 AR 037930 A1 AR037930 A1 AR 037930A1 AR P020105016 A ARP020105016 A AR P020105016A AR P020105016 A ARP020105016 A AR P020105016A AR 037930 A1 AR037930 A1 AR 037930A1
Authority
AR
Argentina
Prior art keywords
acithromycin
tablet
formulations
dry mixture
directly compressible
Prior art date
Application number
ARP020105016A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR037930A1 publication Critical patent/AR037930A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Mezcla en seco, utilizado para formar comprimidos de acitromicina por comprensión directa, que comprende acitromicina no dihidratada y al menos un excipiente farmacéuticamente aceptable. Comprimido de acitromicina que comprende acitromicina no dihidratada y al menos un excipiente farmacéuticamente aceptable. Preferentemente, el comprimido de acitromicina se forma mediante compresión directa de la mezcla seco, de la presente invención, para formar dicho comprimido de acitromicina. Preferiblemente, el comprimido de acitromicina, de la presente invención, contiene una dosificación de 250 mgA, 500 mgA ó 600 mgA de aCItromicina. Comprimido de acitromicina que se produce formando una mezcla en seco de una forma A de acitromicina no granulada, y al menos un excipiente farmacéuticamente aceptable. El comprimido de acitromicina se forma a continuación mediante compresión directas de la mezcla en seco.
ARP020105016A 2001-12-21 2002-12-19 Formulaciones de acitromicina directamente compresibles AR037930A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34348001P 2001-12-21 2001-12-21

Publications (1)

Publication Number Publication Date
AR037930A1 true AR037930A1 (es) 2004-12-22

Family

ID=23346277

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020105016A AR037930A1 (es) 2001-12-21 2002-12-19 Formulaciones de acitromicina directamente compresibles

Country Status (20)

Country Link
US (4) US20030165563A1 (es)
EP (1) EP1455758A1 (es)
JP (1) JP2005513099A (es)
KR (1) KR100632339B1 (es)
CN (1) CN1668282A (es)
AR (1) AR037930A1 (es)
AU (1) AU2002348884A1 (es)
BR (1) BR0215193A (es)
CA (1) CA2469246A1 (es)
IL (1) IL161996A0 (es)
MX (1) MXPA04005105A (es)
NO (1) NO20043110L (es)
NZ (1) NZ532707A (es)
PA (1) PA8562201A1 (es)
PE (1) PE20030591A1 (es)
PL (1) PL371259A1 (es)
RU (1) RU2277914C2 (es)
TW (1) TW200301138A (es)
WO (1) WO2003053416A1 (es)
ZA (1) ZA200403486B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20020231A2 (en) * 2002-03-18 2003-12-31 Pliva D D ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
FR2834889B1 (fr) * 2002-01-18 2004-04-02 Roquette Freres Forme pharmaceutique solide orodispersible
GB0211620D0 (en) * 2002-05-21 2002-07-03 Bioprogress Technology Ltd Powder compaction and enrobing
US20030228370A1 (en) * 2002-06-11 2003-12-11 Michel Serpelloni Orodispersible solid pharmaceutical form
HRP20020614A2 (en) * 2002-07-22 2004-06-30 PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a
EP1648472A2 (en) * 2003-07-01 2006-04-26 Ranbaxy Laboratories, Ltd. Stable oral compositions of azithromycin monohydrate
WO2005004919A2 (en) * 2003-07-02 2005-01-20 Eurand, Inc. Extended release systems for macrolide antibiotics
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
SI1691787T1 (sl) 2003-12-04 2008-10-31 Pfizer Prod Inc Postopek za pripravo farmacevtskih produktov iz več delcev
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
EP1691786A1 (en) 2003-12-04 2006-08-23 Pfizer Products Inc. Multiparticulate compositions with improved stability
AU2004294818A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
US7943585B2 (en) 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
US7468428B2 (en) 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
WO2006067577A2 (en) * 2004-12-21 2006-06-29 Pfizer Products Inc. Stable non-dihydrate azithromycin oral suspensions
US7901710B2 (en) * 2005-08-04 2011-03-08 Vertical Pharmaceuticals, Inc. Nutritional supplement for use under physiologically stressful conditions
US20080045548A1 (en) * 2006-08-21 2008-02-21 Astrazeneca Ab Pharmaceutical Compositions
TWI482772B (zh) * 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
AU2007335155A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc A composition containing a bisphosphonic acid in combination with vitamin D
RU2336073C1 (ru) * 2007-01-10 2008-10-20 Закрытое акционерное общество "Биологические исследования и системы" Пероральный лекарственный препарат тилорон
BRPI0815376A2 (pt) * 2007-07-31 2014-10-07 Cargill Inc Dextrose diretamente compresível
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
WO2009116886A1 (ru) * 2008-03-18 2009-09-24 Dikovskiy Aleksander Vladimiro Фармацевтическая композиция и способ профилактики дисбиозов, ассоциированных с энтеральным приемом антибиотиков
CN101998858A (zh) * 2008-03-18 2011-03-30 亚历山大·弗拉基米罗维奇·季科夫斯基 抗生素和益生元的药物组合物用于预防和治疗抗生素治疗中的微生态失调
US8106111B2 (en) 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
AR083417A1 (es) * 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
WO2013088274A1 (en) 2011-12-14 2013-06-20 Wockhardt Limited Anhydrous amorphous azithromycin composition free of azithromycin dihydrate
KR20150092385A (ko) 2014-02-03 2015-08-13 씨제이헬스케어 주식회사 솔리페나신을 포함하는 안정한 제제 및 이의 제조방법
US10373279B2 (en) 2014-02-24 2019-08-06 Mindojo Ltd. Dynamic knowledge level adaptation of e-learning datagraph structures
US20160145548A1 (en) * 2014-11-20 2016-05-26 The Procter & Gamble Company Cleaning composition refill for an automatic dishwasher dispensing device
CN105193753A (zh) * 2015-10-30 2015-12-30 成都通德药业有限公司 一种阿奇霉素分散片的制备方法
CN110633487B (zh) * 2019-07-03 2023-03-14 北京中医药大学 直接压片的片剂处方的设计方法
CN111467362B (zh) * 2020-05-09 2021-07-06 北京四环制药有限公司 一种阿奇霉素药用组合物及其制备方法和其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
RO107257B1 (ro) * 1987-07-09 1993-10-30 Pfizer Procedeu de obtinere a unui dihidrat de azitromicina, cristalin
WO1989002271A1 (en) * 1987-09-10 1989-03-23 Pfizer Azithromycin and derivatives as antiprotozoal agents
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
TW271400B (es) * 1992-07-30 1996-03-01 Pfizer
EP0758549A4 (en) * 1994-04-26 1997-07-02 Nobuhiro Narita MEDICAL COMPOSITION AS A MEDICINE FOR NON-SMALL CELL CANCER
US5605889A (en) * 1994-04-29 1997-02-25 Pfizer Inc. Method of administering azithromycin
MX9605419A (es) * 1994-05-06 1997-12-31 Pfizer Formas de dosificacion de liberacion controlada de azitromicina.
IL119866A (en) 1996-12-19 1999-12-31 Unipharm Ltd Antibiotic tablet
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US6339063B1 (en) * 1997-09-10 2002-01-15 Merck & Co., Inc. 9a-azalides as veterinary antimicrobial agents
JP2001515865A (ja) * 1997-09-10 2001-09-25 メルク エンド カムパニー インコーポレーテッド 家畜抗菌剤としての９ａ−アザライド
US6245903B1 (en) * 1998-08-21 2001-06-12 Apotex, Inc. Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof
US6365574B2 (en) * 1998-11-30 2002-04-02 Teva Pharmaceutical Industries Ltd. Ethanolate of azithromycin, process for manufacture, and pharmaceutical compositions thereof
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
ES2177373B1 (es) 1999-11-26 2003-11-01 Astur Pharma Sa Preparacion de azitromicina en su forma no cristalina
CA2485433C (en) * 1999-11-26 2008-01-29 Astur Pharma S.A. Preparation of non-crystalline and crystalline dihydrate forms of azithromycin
WO2002009640A2 (en) 2000-08-01 2002-02-07 Shiva Prasad Singh Process for the preparation of anhydrous azithromycin
US6861413B2 (en) * 2001-05-22 2005-03-01 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
IL158591A0 (en) * 2001-05-22 2004-05-12 Pfizer Prod Inc Crystal forms of azithromycin
EP1446010B1 (en) * 2001-10-18 2009-04-15 Teva Pharmaceutical Industries Ltd. Stabilized azithromycin compositions
AU2002348884A1 (en) * 2001-12-21 2003-07-09 Pfizer Products Inc. Directly compressible formulations of azithromycin
WO2003053399A2 (en) * 2001-12-21 2003-07-03 Pfizer Products Inc. Methods for wet granulating azithromycin
CN1646104A (zh) * 2002-02-01 2005-07-27 辉瑞产品公司 阿齐霉素的干颗粒制剂

Also Published As

Publication number Publication date
TW200301138A (en) 2003-07-01
MXPA04005105A (es) 2004-08-19
CA2469246A1 (en) 2003-07-03
RU2004118709A (ru) 2005-04-20
WO2003053416A1 (en) 2003-07-03
JP2005513099A (ja) 2005-05-12
EP1455758A1 (en) 2004-09-15
RU2277914C2 (ru) 2006-06-20
NZ532707A (en) 2006-07-28
US20050287209A1 (en) 2005-12-29
BR0215193A (pt) 2004-11-16
US7070811B2 (en) 2006-07-04
PL371259A1 (en) 2005-06-13
PE20030591A1 (es) 2003-07-12
KR20040066175A (ko) 2004-07-23
US20060024364A1 (en) 2006-02-02
AU2002348884A1 (en) 2003-07-09
CN1668282A (zh) 2005-09-14
IL161996A0 (en) 2005-11-20
US20030165563A1 (en) 2003-09-04
ZA200403486B (en) 2006-05-31
NO20043110L (no) 2004-07-20
KR100632339B1 (ko) 2006-10-12
US20060024363A1 (en) 2006-02-02
PA8562201A1 (es) 2003-07-28

Similar Documents

Publication Publication Date Title
AR037930A1 (es) Formulaciones de acitromicina directamente compresibles
CY1122259T1 (el) Φαρμακοτεχνικη μορφη ταχειας διαλυτοποιησης η οποια περιλαμβανει σινακαλσετη hcl
AR035927A1 (es) Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr
AR022008A1 (es) Una composicion de liberacion controlada de galantamina, un proceso para la preparacion de la misma, y el uso de dicha composicion para la preparacion de un medicamento
CO5190672A1 (es) Composicion para la dosificacion oral, de disolucion instantanea
AR053440A2 (es) Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida
CO5180579A1 (es) Composicion oral solida que comprende levidopa, carbidopa y entacapone
HN1997000151A (es) Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente.
AR065970A2 (es) Una composicion farmaceutica oral solida que comprende una combinacion de metformin y glibenclamida y uso de dicha composicion
NZ507566A (en) Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
UY27296A1 (es) Composición farmacéutica que contiene mosaprida y pancreatina
EA200400352A1 (ru) Органолептически приемлемые распадающиеся во рту композиции
PA8542901A1 (es) Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple
UY27270A1 (es) Comprimido de meloxicam de rápida disgregación
AR036085A1 (es) Formas de dosificacion y procedimiento para su fabricacion
CO5650230A2 (es) Composiciones estables de atorvastatina preparadas con granulacion en humedo
CO5580818A2 (es) Polimorfo cristalino novedoso del clorhidrato de venlafaxina y metodos pra la preparcion del mismo
UY27599A1 (es) Formulaciones de acitromicina directamente compresibles
PL378106A1 (pl) Sposób wytwarzania zawierającej fibrat kompozycji farmaceutycznej w postaci tabletek oraz tabletki otrzymane tym sposobem
AR030660A1 (es) Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12
DE602004022578D1 (de) Antitumorale terpen-verbindungen
PE35498A1 (es) Formulacion farmaceutica de famciclovir
BR0206272A (pt) Forma de dosagem unitária sólida compreendendo citalopram
DK1499278T3 (da) Farmaceutisk doseringsform, som udviser umiddelbar frigivelse, og som omfatter polymorf tibolon

Legal Events

Date Code Title Description
FB Suspension of granting procedure